Frovatriptan: A review

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 1, 2003, Pages 83-94

  Goldstein, Jerome ^a  

^a San Francisco Clinical Research Center   (United States)

Author keywords

Frovatriptan; Headache recurrence; Migraine

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; CYTOCHROME P450 ISOENZYME; DIHYDROERGOTAMINE; ERGOTAMINE; ERGOTAMINE DERIVATIVE; FROVATRIPTAN; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NARCOTIC ANALGESIC AGENT; PLACEBO; PLASMA PROTEIN; RIZATRIPTAN; SEROTONIN 1 AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

AGE; BONE PAIN; BRAIN; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MIGRAINE; NEUROTOXICITY; PARESTHESIA; PATIENT SATISFACTION; RECURRENT DISEASE; REVIEW; SOMNOLENCE; THORAX PAIN;

EID: 0037241440     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.1.83     Document Type: Review

References (33)

1. HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: Classification and diagnostic criteria for headache. Cephalagia (1988) 8(Suppl. 7):1-96.
2. GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine - current understanding and treatment. N. Engl. J. Med. (2002) 346:257-270.
3. OSTERHAUS JT, GUTTERMAN DL, PLACHETKA JR: Healthcare resource and lost labour costs of migraine in the US. Pharmacoeconomics (1992) 2:67-76.
4. SCHOENEN J: Acute migraine therapy: the newer drugs. Curr. Opin. Neurol. (1997) 10:237-243.
5. SHECHTER AL, HOPKINS MM, OSHINSKY M et al.: Acute migraine treatment: patterns of use in a clinical population. 10th Congress of the International Headache Society. New York, USA (2001) Abstract:P1-D6.
6. 1B/1D agonist frovatriptan. Headache (2002) 42(Suppl. 2):S47-S53.
7. 1D receptors. Br. J. Pharmacol. (1999) 127:93P.
8. 1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J. Cardiovasc. Pharmacol. (1998) 32:220-224.
9. BUCHAN P, KEYWOOD C, WADE A et al.: Clinical pharmacokinetics of frovatriptan. Headache (2002) 42(Suppl. 2):S54-S62.
10. RASKIN NH: Migraine and the cluster headache syndrome. In: Harrison's Principles of Internal Medicine (Vol. 1). Fauci AS, Braunwald E, Isselbacher KJ et al. (Eds) 14th edn McGraw Hill, New York, USA (1998):2307-2311.
11. Agents for migraine. In: Drug Facts and Comparisons 2000. 54th edn Facts and Comparisons. St Louis, USA (1999):849.
12. Imitrex (sumatriptan) tablets prescribing information. GlaxoSmithKline, NC, USA (2002).
13. Imitrex (sumatriptan) subcutaneous prescribing information. GlaxoSmithKline, NC, USA (2002).
14. Imitrex (sumatriptan) nasal spray prescribing information. GlaxoSmithKline, NC, USA (2002).
15. Amerge (naratriptan) tablets prescribing information. GlaxoSmithKline, NC, USA (1999).
16. Maxalt (rizatriptan benzoate) tablets and MLT prescribing information, Merck & Co., Inc, NJ, USA (2001).
17. Zomig (zolmitriptan) tablets and ZMT prescribing information, AstraZeneca Pharmaceuticals, DE, USA (2001).
18. Axert (almotriptan malate) tablets prescribing information. Pharmacia Corp., IL, USA (2001).
19. BUCHAN P, WADE A, WARD C et al.: Frovatriptan: a review of drug-drug interactions. Headache (2002) 42(Suppl. 2):S63-S73.
20. GOLDSTEIN J, KEYWOOD C: Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache. (2002) 42:41-48.
21. RAPOPORT A, RYAN R, GOLDSTEIN J et al.: Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache (2002) 42(Suppl. 2):S74-S83.
22. RYAN R, GERAUD G, GOLDSTEIN J et al.: Clinical efficacy of frovatriptan: placebo-controlled studies. Headache (2002) 42(Suppl. 2):S84-S92.
23. MACGREGOR EA, SPIERINGS E: Frovatriptan consistently provides rapid and complete relief in long-term treatment. Headache World 2000. London, UK (2000).
24. MACGREGOR EA, KEYWOOD C: Frovatriptan is effective in menstrually associated migraine. Headache World 2000. London, UK (2000).
25. GOLDSTEIN J, KEYWOOD C, HUTCHISON J: Low 24-hour headache recurrence during treatment with frovatriptan. 9th Congress of the International Headache Society. Barcelona, Spain (1999).
26. 1B/1D agonist. 9th Congress of the International Headache Society. Barcelona, Spain (1999).
27. GERAUD G: Migraine headache recurrence: relationship to clinical, pharmacological and pharmacokinetic properties. Cephalalgia (2001) 21:406.
28. 1B/1D agonist for the acute treatment of migraine, on the cardiovascular system of healthy male volunteers. Headache (1998) 38:388.
29. GERAUD G, SPIERINGS ELH, KEYWOOD C: Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache (2002) 42(Suppl. 2): S93-S99.
30. Wolff's Headache and Other Head Pain. Silberstein SD, Lipton RB, Dalessio DJ (Eds) 7th edn Oxford University Press, Oxford, UK (2001):139.
31. BARTLESON JD: Treatment of migraine headaches. Mayo Clin. Proc. (1999) 74:702-708.
32. LIPTON RB, STEWART WF: Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache (1999) 39(Suppl. 2):S20-S26.
33. STEWART WF, LIPTON RB, CHEE E, SAWYER J, SILBERSTEIN SD: Menstrual cycle and headache in a population sample of migraineurs. Neurology (2000) 55:1517-1523.